1. Home
  2. NICE guidance

Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

Discontinued [GID-TAG393]

  • Project information
  • Project documents

Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients

Prepared by Dr Pelham Barton (West Midlands Health Technology Assessment Collaboration)

Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients Further cost-effectiveness analysis of sequential TNF inhibitors for rheumatoid arthritis patients
29 April 2008
(486.4 Kb 21 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 30 March 2010